| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.46B | 26.50B | 21.36B | 13.72B | 8.42B | 5.40B |
| Gross Profit | 3.59B | 4.92B | 6.42B | 3.75B | 2.11B | 1.38B |
| EBITDA | 1.84B | 1.88B | 4.35B | 1.45B | 819.00M | 559.72M |
| Net Income | -2.17B | -925.00M | 802.00M | 303.00M | 255.71M | 241.42M |
Balance Sheet | ||||||
| Total Assets | 42.22B | 38.99B | 31.52B | 19.21B | 9.02B | 4.79B |
| Cash, Cash Equivalents and Short-Term Investments | 3.62B | 5.64B | 3.31B | 2.61B | 814.76M | 496.36M |
| Total Debt | 26.64B | 22.49B | 20.11B | 11.20B | 6.60B | 3.03B |
| Total Liabilities | 34.32B | 30.37B | 24.38B | 13.84B | 8.15B | 4.09B |
| Stockholders Equity | 7.89B | 8.62B | 7.14B | 4.61B | 864.74M | 693.47M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -2.32B | -2.94B | -741.00M | -78.18M | -392.99M |
| Operating Cash Flow | 0.00 | 1.88B | 2.56B | 1.14B | 378.19M | 201.03M |
| Investing Cash Flow | 0.00 | -4.40B | -5.66B | -2.04B | -633.05M | -648.06M |
| Financing Cash Flow | 0.00 | 4.84B | 3.80B | 2.70B | 573.26M | 489.42M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥30.33B | 17.64 | ― | 2.48% | 3.88% | 0.31% | |
69 Neutral | ¥7.77B | 3.54 | ― | 2.71% | 1.26% | 562.09% | |
65 Neutral | ¥8.64B | 14.97 | ― | ― | 14.05% | -12.70% | |
64 Neutral | ¥7.79B | 13.42 | ― | 1.80% | 18.58% | -6.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥9.09B | -2.93 | ― | ― | 10.09% | -340.83% | |
45 Neutral | ¥7.45B | 27.36 | ― | 1.41% | 18.03% | -11.68% |
Sunwels Co., Ltd. reported highlights for the third quarter of its fiscal year ending March 2026, emphasizing its strategic focus on specialized healthcare and caregiving services. The company underscored initiatives such as the ‘PD House’ for Parkinson’s disease as part of its broader mission to tackle social issues tied to medical care and elder support.
By aligning its business profile with long-term societal needs, Sunwels aims to strengthen its role in sustainable healthcare infrastructure while addressing the growing demand for dedicated caregiving solutions. These efforts suggest a continued push to differentiate its service offerings in a niche but increasingly important segment of the healthcare market, which could enhance its positioning among patients, families, and institutional stakeholders.
The most recent analyst rating on (JP:9229) stock is a Hold with a Yen334.00 price target. To see the full list of analyst forecasts on SUNWELS Co.,Ltd. stock, see the JP:9229 Stock Forecast page.
SUNWELS Co., Ltd. reported non-consolidated net sales of ¥20.73 billion for the nine months ended December 31, 2025, a modest 2.2% increase year on year, but swung to an operating loss of ¥1.19 billion and a net loss of ¥2.06 billion amid a sharp drop in EBITDA. The company’s equity ratio fell from 22.0% to 14.3% as net assets contracted, and management maintained its full-year forecast, projecting higher sales but continued losses and a full-year dividend of zero, underscoring ongoing earnings pressure and a weaker balance sheet for shareholders.
SUNWELS’ balance sheet expanded to total assets of ¥45.69 billion, yet equity declined to ¥6.53 billion, reflecting accumulated losses and putting leverage metrics under strain. With no revisions to earnings or dividend guidance and special accounting methods applied to the quarterly statements, the update signals a challenging transition period in which revenue growth has not translated into profitability, raising concerns about capital strength and future shareholder returns.
The most recent analyst rating on (JP:9229) stock is a Hold with a Yen334.00 price target. To see the full list of analyst forecasts on SUNWELS Co.,Ltd. stock, see the JP:9229 Stock Forecast page.